Comparative analysis of recurrence rates between intravesical gemcitabine and bacillus Calmette–Guérin induction therapy following transurethral resection of bladder tumors in patients with intermediate- and high-risk bladder cancer: A retrospective multicenter study-Reference-Cited by-同舟云学术

Comparative analysis of recurrence rates between intravesical gemcitabine and bacillus Calmette–Guérin induction therapy following transurethral resection of bladder tumors in patients with intermediate- and high-risk bladder cancer: A retrospective multicenter study

Published:2024 Issue:3 Volume:65 Page:248
ISSN:2466-0493
Container-title:Investigative and Clinical Urology
language:en
Short-container-title:Investig Clin Urol

Author:

Choi Joongwon¹^ORCID,Kim Kyung Hwan²^ORCID,Kim Hyung Suk³^ORCID,Yoon Hyun Sik³^ORCID,Kim Jung Hoon¹^ORCID,Kim Jin Wook¹^ORCID,Lee Yong Seong¹^ORCID,Choi Se Young⁴^ORCID,Chang In Ho⁴^ORCID,Ko Young Hwii⁵^ORCID,Song Wan⁶^ORCID,Jeong Byong Chang⁶^ORCID,Nam Jong Kil⁷^ORCID

Affiliation:

1. Department of Urology, Chung-Ang University Gwangmyeong Hospital, Chung-Ang University College of Medicine, Gwangmyeong, Korea.

2. Department of Urology, Pusan National University Hospital, School of Medicine, Pusan National University, Busan, Korea.

3. Department of Urology, Dongguk University Ilsan Medical Center, Dongguk University College of Medicine, Goyang, Korea.

4. Department of Urology, Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, Korea.

5. Department of Urology, Yeungnam University College of Medicine, Daegu, Korea.

6. Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

7. Department of Urology, Pusan National University Yangsan Hospital, School of Medicine, Pusan National University, Yangsan, Korea.

Publisher

XMLink

Link

https://icurology.org/pdf/10.4111/icu.20230313

Reference23 articles.

1. Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non–muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial

2. European Association of Urology (EAU) Prognostic Factor Risk Groups for Non–muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel

3. Management of non-muscle invasive bladder cancer: A comprehensive analysis of guidelines from the United States, Europe and Asia

4. Reduced‐dose bacillus Calmette‐Guérin (BCG) in an era of BCG shortage: real‐world experience from a tertiary cancer centre

5. Intermediate-risk Non–muscle-invasive Bladder Cancer: Updated Consensus Definition and Management Recommendations from the International Bladder Cancer Group

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Short-term outcomes of intravesical gemcitabine for non-muscle-invasive bladder cancer after recent approval for use in Korea;Investigative and Clinical Urology;2024